Access
To read this story in full you will need to login or make a payment (see right).
insight
Nature 415, 234-239 (10 January 2002) | doi:10.1038/415234a
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Gastroenterologist
- Gundersen Lutheran Health System
- La Crosse, Wisconsin, USA
Documentation Specialist Needed For Cutting-Edge Pharma In Cambridge, Ma
- KSR
- Boston, MA, USA
review article Myocardial gene therapy
Jeffrey M. Isner1,
a*We regret the sad news that Dr Jeffrey Isner died suddenly during the latter stages of preparing his Insight Review Article. Nature's editors and colleagues of Dr Isner agreed that his review should be published, and permission to proceed has kindly been given by Dr Isner's next-of-kin. Nature carries sole responsibility for editorial changes made to the article during the production process.
Abstract
Gene therapy is proving likely to be a viable alternative to conventional therapies in coronary artery disease and heart failure. Phase 1 clinical trials indicate high levels of safety and clinical benefits with gene therapy using angiogenic growth factors in myocardial ischaemia. Although gene therapy for heart failure is still at the pre-clinical stage, experimental data indicate that therapeutic angiogenesis using short-term gene expression may elicit functional improvement in affected individuals.
To read this story in full you will need to login or make a payment (see right).
